- Report
- August 2023
- 70 Pages
Spain
From €4531EUR$4,750USD£3,858GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4531EUR$4,750USD£3,858GBP
- Report
- October 2022
- 176 Pages
Global
From €4531EUR$4,750USD£3,858GBP
- Report
- October 2022
- 70 Pages
Africa
From €4531EUR$4,750USD£3,858GBP
- Report
- October 2019
- 125 Pages
Canada
From €4531EUR$4,750USD£3,858GBP
- Report
- March 2019
- 90 Pages
Europe
From €4531EUR$4,750USD£3,858GBP
- Report
- March 2019
- 160 Pages
Middle East, Africa
From €4531EUR$4,750USD£3,858GBP
- Report
- November 2018
- 30 Pages
China
From €2099EUR$2,200USD£1,787GBP
- Report
- February 2018
- 77 Pages
Global
From €2385EUR$2,500USD£2,031GBP
- Report
- May 2023
- 160 Pages
Global
From €5723EUR$5,999USD£4,873GBP
Novolog is a brand of insulin used to treat diabetes, a condition in which the body does not produce or properly use insulin. It is a fast-acting insulin that helps to control blood sugar levels. Novolog belongs to a class of drugs known as endocrine and metabolic disorders drugs, which are used to treat a variety of conditions related to hormones and metabolism. These drugs work by either increasing or decreasing the production of hormones or by altering the way the body uses them.
Novolog is used to treat both type 1 and type 2 diabetes. It is typically taken before meals to help control blood sugar levels. It can also be used in combination with other diabetes medications. Novolog is available in both injectable and inhalable forms.
The Novolog market is highly competitive, with many companies offering similar products. Some of the major players in the market include Novo Nordisk, Eli Lilly, Sanofi, Merck, and AstraZeneca. Show Less Read more